<p>Hantz Financial Services Inc. 在最近向证券交易委员会提交的文件中表示，在第四季度收购了 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 免费报告) 的新股份。该公司收购了 7,827 股生物技术公司的股票，价值约为 839,000 美元。</p>
<p>获取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家大型投资者最近也增加或减少了对该公司的持股。State Street Corp 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 2.7%。State Street Corp 目前拥有 707,414 股生物技术公司的股票，价值 70,805,000 美元，此前在上个季度又收购了 18,642 股。Congress Asset Management Co. 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 3.0%。Congress Asset Management Co. 目前拥有 604,038 股生物技术公司的股票，价值 60,458,000 美元，此前在上个季度又购买了 17,414 股。Chicago Capital LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 6.0%。Chicago Capital LLC 目前拥有 545,821 股生物技术公司的股票，价值 54,631,000 美元，此前在上个季度又购买了 30,875 股。Geode Capital Management LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 5.5%。Geode Capital Management LLC 目前拥有 428,270 股生物技术公司的股票，价值 42,874,000 美元，此前在上个季度又购买了 22,495 股。最后，Loomis Sayles &amp; Co. L P 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 44.3%。Loomis Sayles &amp; Co. L P 目前拥有 372,779 股生物技术公司的股票，价值 37,312,000 美元，此前在上个季度又购买了 114,436 股。机构投资者持有该公司 91.28% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>一些研究分析师最近对该公司进行了评论。加拿大皇家银行在 12 月 11 日的研究报告中将 Ligand Pharmaceuticals 的目标价格从 141.00 美元提高至 143.00 美元，并给予该公司 “跑赢大盘” 的评级。Benchmark 在 12 月 23 日的研究报告中重申了 “买入” 评级，并设定了 135.00 美元的目标价格。巴克莱在 12 月 16 日的研究报告中将 Ligand Pharmaceuticals 的目标价格从 150.00 美元提高至 160.00 美元，并给予该股票 “增持” 评级。Oppenheimer 在 11 月 8 日的研究报告中将 Ligand Pharmaceuticals 的目标价格从 135.00 美元提高至 147.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，HC Wainwright 在 12 月 11 日的研究报告中重申了对 Ligand Pharmaceuticals 的 “买入” 评级。根据 MarketBeat.com 的数据，六位研究分析师对该股票给予了买入评级，Ligand Pharmaceuticals 的平均评级为 “买入”，共识目标价格为 147.00 美元。</p>
<p><strong>阅读我们关于 Ligand Pharmaceuticals 的最新研究报告</strong></p>
<h2>Ligand Pharmaceuticals 的内部活动</h2>
<p>在其他 Ligand Pharmaceuticals 的新闻中，董事 John L. Lamattina 于 11 月 27 日星期三出售了 2,406 股公司的股票。该股票以平均价格 123.65 美元出售，总交易额为 297,501.90 美元。交易完成后，该董事目前拥有 29,515 股公司的股票，价值 3,649,529.75 美元。这代表其持股减少了 7.54%。该交易已在向 SEC 提交的文件中披露，相关文件可在 SEC 网站上找到。此外，首席财务官 Octavio Espinoza 于 12 月 23 日星期一出售了 2,104 股 Ligand Pharmaceuticals 的股票。该股票以平均价格 116.37 美元出售，总价值为 244,842.48 美元。交易完成后，首席财务官目前在公司拥有 20,647 股，价值约为 2,402,691.39 美元。这代表其持股减少了 9.25%。该销售的披露信息可以在这里找到。公司内部人士目前持有 5.90% 的股票。</p>
<h2>Ligand Pharmaceuticals 股票表现</h2>
<p>LGND 股票在周五开盘价为 116.55 美元。该公司的市值为 22 亿美元，市盈率为 46.43，贝塔值为 1.05。Ligand Pharmaceuticals Incorporated 的 52 周低点为 67.72 美元，52 周高点为 129.90 美元。该股票的 50 日移动平均价格为 115.13 美元，200 日移动平均价格为 109.02 美元。</p>
<h2>关于 Ligand Pharmaceuticals</h2>
<p>(免费报告)</p>
<p>Ligand Pharmaceuticals Incorporated 是一家生物制药公司，致力于全球生物制药资产的开发和许可。其商业项目包括用于治疗多发性骨髓瘤的 Kyprolis 和 Evomela；用于治疗急性淋巴细胞白血病或成人和儿童患者淋巴母细胞淋巴瘤的重组厄尔文酶 Rylaze；用于罕见肾病的双重内皮素和血管紧张素 II 受体拮抗剂 Filspari；用于骨质疏松症的特立帕肽注射产品；用于预防由肺炎链球菌血清型引起的侵袭性疾病的 Vaxneuvance；以及帮助抵御儿童肺炎球菌肺炎的肺炎球菌结合疫苗 Pneumosil。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票比 Ligand Pharmaceuticals 更好</li>
<li>消费品股票解析</li>
<li>Nebius Group：市场过度反应还是真正的 AI 颠覆？</li>
<li>股票交易术语 - 每位投资者需要了解的股票术语</li>
<li>投资黄金的最佳方式是...</li>
<li>在 P&amp;G 创下新高之前买入</li>
<li>为什么 Nike 股票可能是 2025 年的最佳反弹股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Ligand 制药吗？</h2>
<p>在考虑 Ligand 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Ligand 制药并不在名单上。</p>
<p>虽然 Ligand 制药目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ligand制药

<p>Hantz Financial Services Inc. 在 Ligand Pharmaceuticals (NASDAQ:LGND) 中获得了约 839,000 美元的新头寸，购买了 7,827 股。其他机构投资者也增加了在 Ligand 的持股，State Street Corp 和 Congress Asset Management Co. 提高了他们的持股比例。分析师对 Ligand 给出了共识 “买入” 评级，目标价格范围在 135 美元到 160 美元之间。最近的内部交易包括董事 John L. Lamattina 和首席财务官 Octavio Espinoza 的股票出售。Ligand 的股票开盘价为 116.55 美元，市值为 22 亿美元</p>

<p>Hantz Financial Services Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The firm acquired 7,827 shares of the biotechnology company's stock, valued at approximately $839,000.</p>
<div class="lb-trans"><p>Hantz Financial Services Inc. 在最近向证券交易委员会提交的文件中表示，在第四季度收购了 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - 免费报告) 的新股份。该公司收购了 7,827 股生物技术公司的股票，价值约为 839,000 美元。</p>
</div><p>Get <strong>Ligand Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ligand Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other large investors also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in shares of Ligand Pharmaceuticals by 2.7% in the 3rd quarter. State Street Corp now owns 707,414 shares of the biotechnology company's stock valued at $70,805,000 after acquiring an additional 18,642 shares in the last quarter. Congress Asset Management Co. raised its stake in Ligand Pharmaceuticals by 3.0% in the third quarter. Congress Asset Management Co. now owns 604,038 shares of the biotechnology company's stock valued at $60,458,000 after purchasing an additional 17,414 shares in the last quarter. Chicago Capital LLC lifted its position in Ligand Pharmaceuticals by 6.0% during the third quarter. Chicago Capital LLC now owns 545,821 shares of the biotechnology company's stock valued at $54,631,000 after purchasing an additional 30,875 shares during the last quarter. Geode Capital Management LLC grew its stake in Ligand Pharmaceuticals by 5.5% in the 3rd quarter. Geode Capital Management LLC now owns 428,270 shares of the biotechnology company's stock worth $42,874,000 after buying an additional 22,495 shares in the last quarter. Finally, Loomis Sayles &amp; Co. L P increased its holdings in shares of Ligand Pharmaceuticals by 44.3% in the 3rd quarter. Loomis Sayles &amp; Co. L P now owns 372,779 shares of the biotechnology company's stock worth $37,312,000 after buying an additional 114,436 shares during the last quarter. Institutional investors own 91.28% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也增加或减少了对该公司的持股。State Street Corp 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 2.7%。State Street Corp 目前拥有 707,414 股生物技术公司的股票，价值 70,805,000 美元，此前在上个季度又收购了 18,642 股。Congress Asset Management Co. 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 3.0%。Congress Asset Management Co. 目前拥有 604,038 股生物技术公司的股票，价值 60,458,000 美元，此前在上个季度又购买了 17,414 股。Chicago Capital LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 6.0%。Chicago Capital LLC 目前拥有 545,821 股生物技术公司的股票，价值 54,631,000 美元，此前在上个季度又购买了 30,875 股。Geode Capital Management LLC 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 5.5%。Geode Capital Management LLC 目前拥有 428,270 股生物技术公司的股票，价值 42,874,000 美元，此前在上个季度又购买了 22,495 股。最后，Loomis Sayles &amp; Co. L P 在第三季度将其在 Ligand Pharmaceuticals 的持股提高了 44.3%。Loomis Sayles &amp; Co. L P 目前拥有 372,779 股生物技术公司的股票，价值 37,312,000 美元，此前在上个季度又购买了 114,436 股。机构投资者持有该公司 91.28% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research analysts recently commented on the company. Royal Bank of Canada increased their target price on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 11th. Benchmark reiterated a &#34;buy&#34; rating and set a $135.00 price objective on shares of Ligand Pharmaceuticals in a research report on Monday, December 23rd. Barclays boosted their target price on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, December 16th. Oppenheimer lifted their price target on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, November 8th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ligand Pharmaceuticals has an average rating of &#34;Buy&#34; and a consensus price target of $147.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司进行了评论。加拿大皇家银行在 12 月 11 日的研究报告中将 Ligand Pharmaceuticals 的目标价格从 141.00 美元提高至 143.00 美元，并给予该公司 “跑赢大盘” 的评级。Benchmark 在 12 月 23 日的研究报告中重申了 “买入” 评级，并设定了 135.00 美元的目标价格。巴克莱在 12 月 16 日的研究报告中将 Ligand Pharmaceuticals 的目标价格从 150.00 美元提高至 160.00 美元，并给予该股票 “增持” 评级。Oppenheimer 在 11 月 8 日的研究报告中将 Ligand Pharmaceuticals 的目标价格从 135.00 美元提高至 147.00 美元，并给予该股票 “跑赢大盘” 的评级。最后，HC Wainwright 在 12 月 11 日的研究报告中重申了对 Ligand Pharmaceuticals 的 “买入” 评级。根据 MarketBeat.com 的数据，六位研究分析师对该股票给予了买入评级，Ligand Pharmaceuticals 的平均评级为 “买入”，共识目标价格为 147.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on Ligand Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Ligand Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Insider Activity at Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ligand Pharmaceuticals 的内部活动</h2>
</div><p>In other Ligand Pharmaceuticals news, Director John L. Lamattina sold 2,406 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $123.65, for a total transaction of $297,501.90. Following the completion of the transaction, the director now owns 29,515 shares of the company's stock, valued at $3,649,529.75. This represents a 7.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Octavio Espinoza sold 2,104 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $116.37, for a total value of $244,842.48. Following the completion of the sale, the chief financial officer now owns 20,647 shares in the company, valued at approximately $2,402,691.39. This represents a 9.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Ligand Pharmaceuticals 的新闻中，董事 John L. Lamattina 于 11 月 27 日星期三出售了 2,406 股公司的股票。该股票以平均价格 123.65 美元出售，总交易额为 297,501.90 美元。交易完成后，该董事目前拥有 29,515 股公司的股票，价值 3,649,529.75 美元。这代表其持股减少了 7.54%。该交易已在向 SEC 提交的文件中披露，相关文件可在 SEC 网站上找到。此外，首席财务官 Octavio Espinoza 于 12 月 23 日星期一出售了 2,104 股 Ligand Pharmaceuticals 的股票。该股票以平均价格 116.37 美元出售，总价值为 244,842.48 美元。交易完成后，首席财务官目前在公司拥有 20,647 股，价值约为 2,402,691.39 美元。这代表其持股减少了 9.25%。该销售的披露信息可以在这里找到。公司内部人士目前持有 5.90% 的股票。</p>
</div><h2>Ligand Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Ligand Pharmaceuticals 股票表现</h2>
</div><p>Shares of LGND stock opened at $116.55 on Friday. The company has a market capitalization of $2.20 billion, a P/E ratio of 46.43 and a beta of 1.05. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $67.72 and a fifty-two week high of $129.90. The stock has a 50 day moving average price of $115.13 and a two-hundred day moving average price of $109.02.</p>
<div class="lb-trans"><p>LGND 股票在周五开盘价为 116.55 美元。该公司的市值为 22 亿美元，市盈率为 46.43，贝塔值为 1.05。Ligand Pharmaceuticals Incorporated 的 52 周低点为 67.72 美元，52 周高点为 129.90 美元。该股票的 50 日移动平均价格为 115.13 美元，200 日移动平均价格为 109.02 美元。</p>
</div><h2>About Ligand Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Ligand Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals Incorporated 是一家生物制药公司，致力于全球生物制药资产的开发和许可。其商业项目包括用于治疗多发性骨髓瘤的 Kyprolis 和 Evomela；用于治疗急性淋巴细胞白血病或成人和儿童患者淋巴母细胞淋巴瘤的重组厄尔文酶 Rylaze；用于罕见肾病的双重内皮素和血管紧张素 II 受体拮抗剂 Filspari；用于骨质疏松症的特立帕肽注射产品；用于预防由肺炎链球菌血清型引起的侵袭性疾病的 Vaxneuvance；以及帮助抵御儿童肺炎球菌肺炎的肺炎球菌结合疫苗 Pneumosil。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Ligand Pharmaceuticals</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Nebius Group: Market Overreaction or Real AI Disruption?</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>The Best Way to Invest in Gold Is...</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>Why Nike Stock Could Be 2025’s Top Comeback Play</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Ligand Pharmaceuticals 更好</li>
<li>消费品股票解析</li>
<li>Nebius Group：市场过度反应还是真正的 AI 颠覆？</li>
<li>股票交易术语 - 每位投资者需要了解的股票术语</li>
<li>投资黄金的最佳方式是...</li>
<li>在 P&amp;G 创下新高之前买入</li>
<li>为什么 Nike 股票可能是 2025 年的最佳反弹股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEdORA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LGND"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ligand 制药吗？</h2>
</div><p>Before you consider Ligand Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ligand 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Ligand 制药并不在名单上。</p>
</div><p>While Ligand Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ligand 制药目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

汉茨金融服务公司在 Ligand 制药公司（纳斯达克股票代码：LGND）持有 83.9 万美元的头寸